首页> 外文期刊>Annals of Clinical and Laboratory Science: Official Journal of the Association of Clinical Scientists >Expression of cytokeratin markers, ER-alpha, PR, HER-2eu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
【24h】

Expression of cytokeratin markers, ER-alpha, PR, HER-2eu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.

机译:细胞角蛋白标志物,ER-alpha,PR,HER-2 / neu和EGFR在乳腺原位导管癌(DCIS)和DCIS与并存的浸润性导管癌(IDC)中的表达。

获取原文
获取原文并翻译 | 示例
           

摘要

Previously, we showed that pure ductal carcinoma in situ (DCIS) of the breast can be divided into 3 subtypes (luminal, basal/stem, and null) based on the expression of 5 cytokeratin (CK) markers: CK5/6, CK14, CK17 (stem/basal), and CK8, CK18 (luminal). The distributions of CK subtypes were associated with nuclear grade and differential expression of estrogen receptor-alpha (ER-alpha), progesterone receptor (PR), HER-2eu, and epidermal growth factor receptor (EGFR). In this study, we further explore the expression patterns of CK markers, ER-alpha, PR, HER-2eu, and EGFR by immunohistochemical (IHC) analysis of 99 cases of pure DCIS and 96 cases of DCIS with co-existing invasive ductal carcinoma (DCIS/IDC). We show that between high-grade DCIS and DCIS/IDC, there are differential expression patterns for ER-alpha, PR, and EGFR in corresponding CK subtypes, suggesting that at least some pure DCIS is molecularly distinct from DCIS/IDC. In most cases there is a high degree of co-expression of these markers between DCIS and the co-existing IDC, suggesting that DCIS is frequently a precursor lesion for co-existing IDC. The rate of discordant expression of these markers is low and is more frequently associated with high-grade carcinoma, suggesting that other molecular pathways also may also be present. There are significant differences in the expression of these molecular markers between high-grade and non-high-grade carcinomas, supporting the view that high-grade and non-high-grade carcinomas of the breast are molecularly distinct entities.
机译:之前,我们根据5种细胞角蛋白(CK)标记的表达将纯乳腺导管原位癌(DCIS)分为3种亚型(腔,基底/茎和空),分别为:CK5 / 6,CK14, CK17(茎/基),以及CK8,CK18(内腔)。 CK亚型的分布与雌激素受体α(ER-α),孕激素受体(PR),HER-2 / neu和表皮生长因子受体(EGFR)的核级和差异表达有关。在这项研究中,我们通过免疫组化(IHC)分析99例纯DCIS和96例DCIS并存的浸润性肝癌,进一步探讨CK标记,ER-alpha,PR,HER-2 / neu和EGFR的表达模式导管癌(DCIS / IDC)。我们显示,在高级DCIS和DCIS / IDC之间,相应的CK亚型中存在ER-α,PR和EGFR的差异表达模式,这表明至少某些纯DCIS在分子上与DCIS / IDC不同。在大多数情况下,这些标记在DCIS与并存的IDC之间高度共表达,这表明DCIS通常是IDC共存的前体病变。这些标记的不一致表达率很低,并且更常与高级别癌相关,表明也可能存在其他分子途径。这些分子标志物的表达在高等级和非高等级癌症之间存在显着差异,支持这样的观点,即乳腺癌的高等级和非高等级癌症是分子上不同的实体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号